These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 14718699)

  • 1. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
    Reines SA; Block GA; Morris JC; Liu G; Nessly ML; Lines CR; Norman BA; Baranak CC;
    Neurology; 2004 Jan; 62(1):66-71. PubMed ID: 14718699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
    Thal LJ; Ferris SH; Kirby L; Block GA; Lines CR; Yuen E; Assaid C; Nessly ML; Norman BA; Baranak CC; Reines SA;
    Neuropsychopharmacology; 2005 Jun; 30(6):1204-15. PubMed ID: 15742005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
    Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
    Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins.
    Sculean A; Berakdar M; Donos N; Auschill TM; Arweiler NB
    Clin Oral Investig; 2003 Jun; 7(2):108-12. PubMed ID: 12720115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
    Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Moric M; Rosenberg AG
    JAMA; 2003 Nov; 290(18):2411-8. PubMed ID: 14612477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty.
    Reuben SS; Fingeroth R; Krushell R; Maciolek H
    J Arthroplasty; 2002 Jan; 17(1):26-31. PubMed ID: 11805921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
    Laine L; Harper S; Simon T; Bath R; Johanson J; Schwartz H; Stern S; Quan H; Bolognese J
    Gastroenterology; 1999 Oct; 117(4):776-83. PubMed ID: 10500058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
    Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
    Am J Med; 2000 Aug; 109(3):201-6. PubMed ID: 10974182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry.
    Jackson ID; Heidemann BH; Wilson J; Power I; Brown RD
    Br J Anaesth; 2004 May; 92(5):675-80. PubMed ID: 15033894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial.
    Morrison BW; Christensen S; Yuan W; Brown J; Amlani S; Seidenberg B
    Clin Ther; 1999 Jun; 21(6):943-53. PubMed ID: 10440619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.